<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01037387</url>
  </required_header>
  <id_info>
    <org_study_id>HULP PI-825</org_study_id>
    <nct_id>NCT01037387</nct_id>
  </id_info>
  <brief_title>Effect of Noninvasive Ventilation on Physical Activity and Inflammation in COPD Patients</brief_title>
  <official_title>Effect of the Noninvasive Mechanical Ventilation on the Daily Physical Activity and the Inflammatory Biomarkers in Stable Patients With COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario La Paz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitario La Paz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Parallel, randomized and controlled clinical trial to evaluate the effect of 12 months of
      noninvasive mechanical ventilation versus conventional treatment in hypercapnic patients with
      stable COPD.

      Main objective: To evaluate the effect of 12 months of noninvasive ventilation on c-reactive
      protein concentration and daily physical activity in hypercapnic patients with stable COPD.

      Secondary objectives: To compare the plasmatic concentration of other inflammatory biomarkers
      between COPD patients with conventional treatment and wich noninvasive ventilation. To
      determine the response of breathlessness, health-related quality of life and lung function to
      noninvasive ventilation. To identify the COPD patients with a higher gasometric and clinic
      response to noninvasive ventilation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>daily physical activity and plasmatic concentration of C-reactive protein</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seric concentrations of homocysteine, proBNP, fibrinogen, cholesterol, tg, tnf-alpha, IL-1, IL-6 and 8-isoprostane</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PaO2, PaCO2, pH, IC, VCIN, FVC, FEV1, FEV1/FVC, TLC, FRC/TLC, RV/TLC,PImax, PEmax, TTmus, 6MWD</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BDI/TDI, SF-36, SGRQ, LCADL</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular effects, exacerbations, hospitalizations and mortality</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <condition>Hypercapnic</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional treatment for COPD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NIMV group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NIMV: Conventional treatment plus noninvasive mechanical ventilation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Current treatment according to the ATS/ERS guidelines</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Bronchodilator agents and inhaled corticosteroids</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NIMV group</intervention_name>
    <description>Current treatment according to the ATS/ERS guidelines and nocturnal BiPAP (IPAP 10-20 cmH2O,EPAP 4-6 cmH2O).</description>
    <arm_group_label>NIMV group</arm_group_label>
    <other_name>Bronchodilator agents and inhaled corticosteroids.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 45-75 yrs.

          -  COPD diagnosis (postbronchodilator FEV1/FVC &lt; 0.7) for at least 6 months.

          -  FEV1 &lt; 45% predicted

          -  Baseline pH 7.35-7.45

          -  Baseline PaCO2&gt;45 mmHg breathing current air

          -  Smoking history (&gt;15 pack-year)

          -  Clinically stable for at least the last three months

          -  Pharmacological treatment optimized in the last two years.

        Exclusion Criteria:

          -  Previous diagnosis of asthma, other airway obstructive disease, sleep apnea syndrome,
             interstitial lung disease, chest wall disease or neuromuscular disease.

          -  Apnea-hypopnea index &gt; 10/h

          -  Morbid obesity (BMI &gt; 45 Kg/m2)

          -  Previous diagnosis of ischaemic heart disease, cardiac failure, cirrhosis, chronic
             renal failure, rheumatoid arthritis or other inflammatory disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Antonia Gómez-Mendieta</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario La Paz</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>María Antonia Gomez-Mendieta, MD</last_name>
    <phone>34917277253</phone>
    <email>fgr01m@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>María Antonia Gómez-Mendieta, MD</last_name>
      <phone>917277253</phone>
      <email>fgr01m@gmail.com</email>
    </contact>
    <investigator>
      <last_name>María Antonia Gomez-Mendieta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claudia Llontop</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francisco Garcia-Rio, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2009</study_first_submitted>
  <study_first_submitted_qc>December 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2009</study_first_posted>
  <last_update_submitted>June 24, 2016</last_update_submitted>
  <last_update_submitted_qc>June 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitario La Paz</investigator_affiliation>
    <investigator_full_name>Francisco Garcia-Rio</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Hypercapnia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchodilator Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

